Exeliom is happy to report that the first participant has been enrolled in our BIG clinical trial in immuno-oncology!

This crucial study investigates the efficacy of EXL01 as an adjuvant in the treatment of gastric cancer. With almost one million new cases diagnosed each year, this is a major research area that demands effective and accessible treatment.

We would like to thank GERCOR for leading the trial. As a non-profit organization with a network of over 300 centers, its mission is to improve treatments for solid tumor cancer patients.

Stay tuned for further updates